Research Article
miR-149-3p Is a Potential Prognosis Biomarker and Correlated with Immune Infiltrates in Uterine Corpus Endometrial Carcinoma
Table 1
Correlation between miR-149-3p expression and clinical characteristics in UCEC.
| | Characteristic | Levels | Overall | Low expression of hsa-miR-149-3p | High expression of hsa-miR-149-3p | |
| | n | | 546 | 273 | 273 | | | Clinical stage, n (%) | Stage I | 341 (62.5%) | 182 (33.3%) | 159 (29.1%) | 0.208 | | Stage II | 49 (9%) | 21 (3.8%) | 28 (5.1%) | | Stage III | 128 (23.4%) | 56 (10.3%) | 72 (13.2%) | | Stage IV | 28 (5.1%) | 14 (2.6%) | 14 (2.6%) | | Primary therapy outcome, n (%) | PD | 20 (4.2%) | 7 (1.5%) | 13 (2.7%) | 0.080 | | SD | 6 (1.3%) | 4 (0.8%) | 2 (0.4%) | | PR | 12 (2.5%) | 3 (0.6%) | 9 (1.9%) | | CR | 437 (92%) | 235 (49.5%) | 202 (42.5%) | | Race, n (%) | Asian | 20 (4%) | 14 (2.8%) | 6 (1.2%) | 0.118 | | Black or African American | 109 (21.8%) | 49 (9.8%) | 60 (12%) | | White | 372 (74.3%) | 185 (36.9%) | 187 (37.3%) | | Age, n (%) | ≤60 | 205 (37.8%) | 125 (23%) | 80 (14.7%) | <0.001 | | >60 | 338 (62.2%) | 148 (27.3%) | 190 (35%) | | Weight, n (%) | ≤80 | 240 (45.9%) | 113 (21.6%) | 127 (24.3%) | 0.133 | | >80 | 283 (54.1%) | 153 (29.3%) | 130 (24.9%) | | Height, n (%) | ≤160 | 244 (47%) | 127 (24.5%) | 117 (22.5%) | 0.616 | | >160 | 275 (53%) | 136 (26.2%) | 139 (26.8%) | | BMI, n (%) | ≤30 | 209 (40.6%) | 104 (20.2%) | 105 (20.4%) | 0.743 | | >30 | 306 (59.4%) | 158 (30.7%) | 148 (28.7%) | | Histological type, n (%) | Endometrioid | 409 (74.9%) | 233 (42.7%) | 176 (32.2%) | <0.001 | | Mixed | 24 (4.4%) | 9 (1.6%) | 15 (2.7%) | | Serous | 113 (20.7%) | 31 (5.7%) | 82 (15%) | | Residual tumor, n (%) | R0 | 371 (90.9%) | 192 (47.1%) | 179 (43.9%) | 0.432 | | R1 | 22 (5.4%) | 10 (2.5%) | 12 (2.9%) | | R2 | 15 (3.7%) | 10 (2.5%) | 5 (1.2%) | | Histologic grade, n (%) | | 98 (18.3%) | 72 (13.5%) | 26 (4.9%) | <0.001 | | 121 (22.6%) | 78 (14.6%) | 43 (8%) | | 316 (59.1%) | 121 (22.6%) | 195 (36.4%) | | Tumor invasion (%), n (%) | <50 | 260 (55.3%) | 152 (32.3%) | 108 (23%) | 0.014 | | ≥50 | 210 (44.7%) | 98 (20.9%) | 112 (23.8%) | | Menopause status, n (%) | Pre | 34 (6.8%) | 21 (4.2%) | 13 (2.6%) | 0.360 | | Peri | 17 (3.4%) | 9 (1.8%) | 8 (1.6%) | | Post | 449 (89.8%) | 221 (44.2%) | 228 (45.6%) | | Hormones therapy, n (%) | No | 297 (86.6%) | 158 (46.1%) | 139 (40.5%) | 0.806 | | Yes | 46 (13.4%) | 23 (6.7%) | 23 (6.7%) | | Diabetes, n (%) | No | 323 (72.6%) | 165 (37.1%) | 158 (35.5%) | 0.475 | | Yes | 122 (27.4%) | 57 (12.8%) | 65 (14.6%) | | Radiation therapy, n (%) | No | 278 (53.4%) | 157 (30.1%) | 121 (23.2%) | 0.011 | | Yes | 243 (46.6%) | 109 (20.9%) | 134 (25.7%) | | Surgical approach, n (%) | Minimally invasive | 207 (39.6%) | 113 (21.6%) | 94 (18%) | 0.197 | | Open | 316 (60.4%) | 153 (29.3%) | 163 (31.2%) | | Age, median (IQR) | | 64 (57, 71) | 62 (55, 69) | 66 (59, 72) | <0.001 |
|
|
